Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

Overview

This study will assess the safety, tolerability, and effect of TAP311 on blood lipids in healthy subjects and in patients who have dyslipidemia. The effect of food on TAP311 concentration in blood and effect of TAP311 administration on simvastatin concentration will also be assessed in healthy volunteers.

Full Title of Study: “A First-in-human Randomized, Double-blind, Placebo-controlled, 4-part Study to Assess Safety, Tolerability, Pharmacokinetics (Including Open Label Study of Food Effect and Interaction With Simvastatin) and Pharmacodynamics of Interwoven Single- and Multiple-ascending Doses of TAP311 in Healthy Subjects and Dyslipidemic Patients.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: June 2012

Interventions

  • Drug: TAP311

Arms, Groups and Cohorts

  • Experimental: TAP311 in Healthy Volunteers
  • Placebo Comparator: Matching Placebo
    • Healthy Volunteers and Patients will be treated in Placebo group.
  • Experimental: TAP311 and Simvastatin
  • Experimental: TAP311 in Patients

Clinical Trial Outcome Measures

Primary Measures

  • Safety and tolerability of single and multiple doses of TAP311 in healthy subjects and patients with dyslipidemia
    • Time Frame: Up to 21 days
    • Number of patients with adverse events and changes from baseline in vital signs, ECG and clinical labs (blood chemistry, hematology and urinalysis).

Secondary Measures

  • TAP311 concentrations in blood and urine following administration of single and multiple doses in healthy subjects and in patients with dyslipidemia.
    • Time Frame: 25 timepoints over 17 days
  • Effect of TAP311 administration on simvastatin (and metabolite) blood concentration in healthy subjects.
    • Time Frame: 10 days
    • Simvastatin (and metabolite) blood concentration before and after TAP311 treatment.
  • Effect of food on TAP311 blood concentration in healthy subjects.
    • Time Frame: 3 days
    • TAP311 blood concentration when the drug is administered with and without food.
  • Effects of TAP311 on total cholesterol in patients with dyslipidemia
    • Time Frame: 8 timepoints over 15 days
    • Total cholesterol blood concentration before and after TAP311 treatment.
  • Effects of TAP311 on Low Density Lipoprotein (LDL-C) in patients with dyslipidemia
    • Time Frame: 8 timepoints over 15 days
    • LDL-C blood concentration before and after TAP311 treatment.
  • Effects of TAP311 on high density lipoprotein (HDL-C)in patients with dyslipidemia.
    • Time Frame: 8 timepoints over 15 days
    • HDL-C blood concentration before and after TAP311 treatment.
  • Effects of TAP311 on triglycerides in patients with Dyslipidemia
    • Time Frame: 8 timepoints over 15 days
    • Triglycerides concentration in blood before and after TAP311 treatment.

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy male and female subjects age 18 to 65 years of age included, and in good health as determined by past medical history, physical examination, electrocardiogram, and laboratory tests at screening. – OR untreated dyslipidemic patients. – Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 – 36 kg/m2. – Able to communicate well with the investigator, to understand and comply with the requirements of the study. Exclusion Criteria:

  • Use of other investigational drugs at the time of enrollment. – Active treatment for type 1 diabetes or type 2 diabetes mellitus. – A past medical history of ECG abnormalities, documented cardiac arrhythmias or cardiovascular diseases. – History of malignancy of any organ system, treated or untreated, within the past 5 years. – Pregnant or nursing (lactating) women. – Smokers. – Use of any prescription drugs, herbal supplements and/or over-the-counter (OTC) medication, dietary supplements. – History of drug or alcohol abuse within the 12 months prior to dosing. – Any surgical or medical condition, acute or unstable chronic disease which may, based on the investigator's opinion, jeopardize the patient in case of participation in the study Other protocol-defined inclusion/exclusion criteria may apply.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Novartis Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Novartis Pharmaceuticals, Study Director, Novartis Pharmaceuticals

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.